Accipiter Capital Management LLC Has Cut Its Holding in Teva Pharm Adr (TEVA) by $4.70 Million

June 17, 2018 - By Peter Erickson

Teva Pharmaceutical Industries Limited (NYSE:TEVA) Logo

Gabe Hoffman decreased its stake in Teva Pharm Adr (TEVA) by 65.2% based on its latest 2018Q1 regulatory filing with the SEC. Accipiter Capital Management Llc sold 276,493 shares as the company’s stock rose 10.90% while stock markets declined. The hedge fund run by Gabe Hoffman held 147,571 shares of the major pharmaceuticals company at the end of 2018Q1, valued at $2.52M, down from 424,064 at the end of the previous reported quarter. Accipiter Capital Management Llc who had been investing in Teva Pharm Adr for a number of months, seems to be less bullish one the $24.20 billion market cap company. The stock decreased 0.08% or $0.02 during the last trading session, reaching $23.76. About 7.58M shares traded. Teva Pharmaceutical Industries Limited (NYSE:TEVA) has declined 22.74% since June 17, 2017 and is downtrending. It has underperformed by 35.31% the S&P500.

Accipiter Capital Management Llc, which manages about $316.20M and $47.37M US Long portfolio, upped its stake in Shire Plc (NASDAQ:SHPG) by 30,027 shares to 80,270 shares, valued at $11.99 million in 2018Q1, according to the filing.

Analysts await Teva Pharmaceutical Industries Limited (NYSE:TEVA) to report earnings on August, 2. They expect $0.62 earnings per share, down 37.37 % or $0.37 from last year’s $0.99 per share. TEVA’s profit will be $631.46M for 9.58 P/E if the $0.62 EPS becomes a reality. After $0.91 actual earnings per share reported by Teva Pharmaceutical Industries Limited for the previous quarter, Wall Street now forecasts -31.87 % negative EPS growth.

More notable recent Teva Pharmaceutical Industries Limited (NYSE:TEVA) news were published by: which released: “Teva Pharmaceutical Industries Limited Stock Still Is a Deep Value Play” on June 15, 2018, also with their article: “Warren Buffett Loves TEVA Stock and You Should Too” published on May 23, 2018, published: “Buy Alibaba – Cramer’s Lightning Round (6/12/18)” on June 13, 2018. More interesting news about Teva Pharmaceutical Industries Limited (NYSE:TEVA) were released by: and their article: “Analysis: Positioning to Benefit within Teva Pharmaceutical Industries, Resonant, United Community Financial …” published on June 07, 2018 as well as Globes.Co.Il‘s news article titled: “Tue: Teva rally fails to lift TASE” with publication date: June 12, 2018.

Teva Pharmaceutical Industries Limited (NYSE:TEVA) Ratings Coverage

Among 21 analysts covering Teva Pharma (NYSE:TEVA), 5 have Buy rating, 4 Sell and 12 Hold. Therefore 24% are positive. Teva Pharma has $2700 highest and $13.0 lowest target. $19.50’s average target is -17.93% below currents $23.76 stock price. Teva Pharma had 37 analyst reports since December 18, 2017 according to SRatingsIntel. Citigroup maintained the stock with “Buy” rating in Thursday, May 31 report. The rating was upgraded by Cantor Fitzgerald on Friday, December 22 to “Hold”. The rating was maintained by Guggenheim with “Hold” on Tuesday, January 16. The rating was upgraded by Goldman Sachs to “Buy” on Thursday, January 11. Jefferies maintained the stock with “Hold” rating in Tuesday, March 20 report. Cowen & Co maintained Teva Pharmaceutical Industries Limited (NYSE:TEVA) on Thursday, February 8 with “Hold” rating. The stock of Teva Pharmaceutical Industries Limited (NYSE:TEVA) has “Sell” rating given on Thursday, May 3 by Wells Fargo. On Thursday, May 24 the stock rating was maintained by Guggenheim with “Hold”. The firm earned “Underweight” rating on Friday, February 9 by PiperJaffray. On Tuesday, January 30 the stock rating was maintained by Piper Jaffray with “Hold”.

Teva Pharmaceutical Industries Limited (NYSE:TEVA) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.